Too many middlemen disconnects you from patients.

See How Close
Lost in Transition Telephones
Lost in Transition

Treating rare disease shouldn’t be like a bad game of telephone, with each step generating chaos and confusion. Patient adherence suffers, quality of care diminishes, manufacturers miss out on vital feedback and cost goes up. But imagine if you could cut past all that. We did.

Learn More

Biopharma Brand

Best-in-class expertise for drug and device manufacturers


Staying lean creates maximum commercial business value


  • A private equity firm had its eye on a rare disease start-up, but knew the cost to commercialize was unpredictable and risky
  • The firm needed an experienced channel support partner with the infrastructure and operational processes already in place to help lead product launch, government pricing and accounts receivables management.
  • Recognizing customer satisfaction was paramount to its future business valuation, the firm needed a partner that it could trust to uphold its brand reputation in the marketplace.


  • From there, the DLSS team applied its proven operational expertise to work closely with the client to tailor a comprehensive, back-office service offering.
  • From financial services to logistics to reimbursement strategies, DLSS provided the right resources and expertise so the client didn’t have to waste time and money building and managing functional support departments.
  • Leveraging our capabilities in managing day-to-day operations allowed the client to focus on building its product portfolio and meeting their growth targets


  • The value of staying virtual paid off. The rare disease business was positioned well for valuation and the equity firm could successfully move to their next investment.
  • When the equity firm was ready to make their next investment, they brought DLSS to the table - reinforcing the financial and strategic value of intelligent outsourcing.